This is the first study that demonstrates RABEX-5 mRNA to be an independent prognosticator in prostate cancer with high RABEX-5 mRNA expression indicating
poor outcome. The finding that patients with high RABEX-5 mRNA expressing tumors have worse biochemical recurrence free and overall survival than patients with low RABEX-5 mRNA expressing tumors indicates that RABEX-5 mRNA has the potential to be used as a useful prognostic biomarker in prostate cancer. Consequently, RABEX-5 mRNA expression, if validated in future studies, could be used for selection of prostate cancer patients for adjuvant treatment following radical prostatectomy. Overall, our data show that high RABEX-5 mRNA expression profile correlates with poor prognosis in prostate cancer. Conclusions In conclusions, RABEX-5 was found to be overexpressed at the mRNA level in prostate cancer samples examined compared to adjacent non-cancerous tissues from the same patient. Our LY2874455 in vivo current work demonstrates that NVP-BGJ398 mw RABEX-5 mRNA expression levels are associated with lymph node metastasis, clinical stage, preoperative
prostate-specific antigen, biochemical recurrence, and Gleason score. RABEX-5 may play an important role in prostate cancer development. Our study has laid a foundation for future investigations to further explore the potential of RABEX-5 mRNA as a diagnostic marker for monitoring biochemical recurrence and as an effective therapeutic target for preventing and treating prostate cancer. Consent Written informed consent was obtained from the Cisplatin purchase patient for publication of this report and any accompanying images. Acknowledgements This study was supported by the National Natural Science Foundation of China (NO: 81172451), and Science Foundation of Tianjin medical university. (NO: 2009GSI18). References 1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer
J Clin 2012,62(1):10–29.PubMedCrossRef Sinomenine 2. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R: Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res 2012, 31:32.PubMedCentralPubMedCrossRef 3. Petrongari MG, Landoni V, Saracino B, Gomellini S, Arcangeli S, Iaccarino G, Pinnarò P, Arcangeli G, Strigari L: Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res 2013,32(1):103.PubMedCentralPubMedCrossRef 4. Fukuda M: Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci 2008, 65:2801–2813.PubMedCrossRef 5. Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 2009, 10:513–525.PubMedCrossRef 6. Barr F, Lambright DG: Rab GEFs and GAPs. Curr Opin Cell Biol 2010, 22:461–470.PubMedCentralPubMedCrossRef 7.